Скачать или смотреть CALQUENCE® (acalabrutinib) Mechanism of Action (MOA) - Dr Pearson, MD

Please see full Prescribing Information: https://qr.short.az/CalquenceUSPI
This video is intended for US healthcare professionals only.

Edward James Pearson, MD, discusses the mechanism of action (MOA) of CALQUENCE and how it works to inhibit BTK.

Topics include B-cell receptor signaling, selectivity of kinase inhibition, and targeting BTK.

Indication and Select Safety Information
CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) are diarrhea, upper respiratory tract infection, headache, musculoskeletal pain, lower respiratory tract infection, and fatigue. The most common Grade 3 or 4 laboratory abnormalities (≥10%) are absolute neutrophil count decreased, absolute lymphocyte count decreased, platelets decreased, and hemoglobin decreased.